The investigational monoclonal antibody barzolvolimab significantly improved provocation test outcomes and reduced symptoms compared with placebo in patients with cold urticaria and symptomatic ...
In children evaluated for a possible macrolide allergy, intradermal testing with a suspected culprit drug at 0.05 mg/mL showed high specificity (92.7%) but limited sensitivity. To confirm an allergy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results